Analytical Data
-
基因名
TCL1A
- Application
-
别名
Tgtp; TCL1A; TCL1; T-Cell Specific GTPase; Oncogene TCL1; Protein p14 TCL1
-
种属
Human
-
表达系统
E. coli
-
标签
N-His
-
纯度
Greater than 95% as determined by SDS-PAGE.
-
蛋白编号
P56279
-
表达区间
Met1~Asp114
-
分子量
17kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
TCL1A, or T-cell leukemia 1A, is a gene that has garnered significant attention in the field of cancer research, particularly for its role in T-cell malignancies such as T-cell acute lymphoblastic leukemia (T-ALL). The TCL1A protein is known to function as an oncogene, promoting cell survival and proliferation by modulating cellular pathways related to apoptosis and T-cell activation. Research has shown that TCL1A can be upregulated in certain leukemic cells, leading to increased tumorigenicity. This has prompted investigations into the mechanisms behind its overexpression and functional roles in malignant transformation. Studies have utilized recombinant TCL1A proteins to explore their interactions with various cellular partners and signaling pathways, enhancing our understanding of how aberrant TCL1A activity contributes to T-cell leukemogenesis. The development of targeted therapies aimed at inhibiting TCL1A and its downstream effects represents a promising avenue for improving treatment outcomes in patients with TCL1A-related malignancies. Overall, the study of TCL1A and its recombinant forms is vital for uncovering new therapeutic targets and elucidating the complex biology underlying T-cell cancers.
